Canada markets closed

Numinus Wellness Inc. (NUMIF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.0518-0.0004 (-0.77%)
At close: 02:53PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close0.0522
Open0.0525
BidN/A x N/A
AskN/A x N/A
Day's Range0.0513 - 0.0530
52 Week Range0.0500 - 0.2010
Volume67,085
Avg. Volume288,614
Market Cap16.605M
Beta (5Y Monthly)1.46
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
All
News
  • CNW Group

    Cedar Clinical Research selected as clinical research site for Cybin's Phase 3 Study of CYB003

    Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing traditional and innovative behavioral health treatments with a focus on safe, evidence-based novel therapies, is proud to announce that its research site, Cedar Clinical Research ("CCR"), has been chosen as one of multiple sites for Cybin's Phase 3 pivotal, multinational clinical trial of CYB003 for the adjunctive treatment of Major Depressive Disorder ("MDD").

  • PR Newswire

    Numinus Wellness Provides Corporate Update

    Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing traditional and innovative behavioral health treatments with a focus on safe, evidence-based psychedelic-assisted therapies, provides an update following unauthorized disclosure in an online newspaper which has come to its attention.

  • PR Newswire

    Numinus Wellness Inc. Announces Second Quarter Fiscal 2024 Results

    Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing traditional and innovative behavioral health treatments with a focus on safe, evidence-based psychedelic-assisted therapies, today announced its financial results for the three months ended February 29, 2024 ("Q2 2024").